Global Atherosclerosis Market Overview:
Atherosclerosis is when the blood vessels become hard due to buildup of plaque. The artery becomes narrow and harden because of the buildup plaque this limits the flow of oxygen-rich blood to your organs and other parts of your body. Plaque is made up of cholesterol, fat, calcium, and other elements that are found in the blood. Plague can lead to serious problems, like heart attack, stroke, or even death.
- Increasing Number of Patients Suffering From Coronary Heart Disease
- Rising Number of Aging Population
- Advanced Diagnostic Techniques Employed For Diagnosis of Atherosclerosis
- Adequate Definitive Treatment
- Limited Availability of Drugs
- Rising Emphasis on Identification of New Drug for Atherosclerosis
Some of the key players profiled in the report are AstraZeneca Plc (United Kingdom), Bayer AG (Germany), Merck and Co. Inc. (United States), Novartis AG (Switzerland), Sanofi (France), Anthera Pharmaceuticals (United States), Taxus Cardium (United States), F. Hoffmann-La Roche Ltd. (Switzerland), GlaxoSmithKline plc. (United Kingdom), Ionis Pharmaceuticals, Inc. (United States), Johnson and Johnson (United States) and Merck & Co., Inc. (United States). Analyst at AdvanceMarketAnalytics see European Players to retain maximum share of Global Atherosclerosis market by 2025. Considering Market by Treatment, the sub-segment i.e. Medication will boost the Atherosclerosis market. Considering Market by Distribution Channel, the sub-segment i.e. Hospital Pharmacies will boost the Atherosclerosis market.
On December 17, 2019 - Roche and Spark Therapeutics, Inc. (“Spark”) today announced the completion of the acquisition. Roche and Spark will be able to significantly improve the lives of patients through innovative gene therapies. This acquisition supports Roche long-lasting commitment to bringing transformational therapies and innovative approaches to people around the world with serious diseases.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be provided prior to purchase
The top-down and bottom-up approaches are used to estimate and validate the size of the Global Atherosclerosis market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Atherosclerosis market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes Service Providers of Atherosclerosis, Pharmaceutical Industry, Regulatory Bodies and Governmental Bodies.
This helps us to gather the data related to players revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, USPTO, EPO, Annual reports, press releases etc.